In another study in acute leukemia patients, the effects of PI3K/AKT/mTOR inhibitors and insulin varied among the patient subsets, and it was noted that the variations in insulin responsiveness are associated with differential susceptibility to metabolic targeting [100]. This evidence concerns the gene INS and acute leukemia.